Bruker has announced the release of iNTApharma™, a new label-free platform designed to characterize nanoparticles used in mRNA drug development and gene therapy quality control. The technology aims to provide detailed analysis of nanoparticle size, concentration, and stability without the need for fluorescent or other labels.
The platform is intended to support pharmaceutical researchers and manufacturers by offering precise and efficient nanoparticle characterization, which is critical for ensuring the safety and effectiveness of mRNA-based therapies and gene therapies.
**Why this matters**
Accurate nanoparticle characterization is essential in the development and quality control of mRNA drugs and gene therapies, as these therapies rely on nanoparticles to deliver genetic material into cells. A label-free method like iNTApharma™ can streamline testing processes, reduce potential interference from labeling agents, and improve the reliability of data used to assess drug formulations.
Source: NewsData